PTO/SB/08 (09-06)

Approvement use through 03/31/2007, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO				Complete if Known			
·	INFORMATION DIS	SCLO	SURE	Application Number	10/681,418		
STATEMENT BY APPLICANT				Filing Date	10/7/2003		
	Data Submitted: Au	ouet 0	· 2007	First Named Inventor	H. Michael SHEPARD		
Date Submitted: August 9, 2007 (use as many sheets as necessary)				Art Unit	1623		
				Examiner Name Lawrence E. Crane			
Sheet	1	of	1	Attorney Docket Number	NB 2008.01 (060925-0801)		

U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
		Number-Kind Code ² (if known)			Passages or Relevant Figures Appear	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
					rigures Appear	

		<u> </u>	FOREIGN PATENT D	DCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁶ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
						1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	⊤6		
Me	AR5	LIBRA et al. (2004) Thymidylate synthase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy, BMC Cancer 4:11			

		<u> </u>		<u> </u>
Examiner Signature	L. E. Crane	Mr Cyan	Date Considered	10/18/2007

*EXAMINER: Initial if reference considered, whether or not fation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to apply ant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspip.gov or MPEP 901.04. 3 Enter Office that is used the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SVCA_69489.1